Reevaluation of lock solutions for Central venous catheters in hemodialysis: a narrative review
- PMID: 36047812
- PMCID: PMC9448397
- DOI: 10.1080/0886022X.2022.2118068
Reevaluation of lock solutions for Central venous catheters in hemodialysis: a narrative review
Abstract
Background: A significant proportion of incident and prevalent hemodialysis patients have central venous catheters for vascular access. No consensus is available on the prevention of catheter dysfunction or catheter-related bloodstream infections in patients undergoing hemodialysis by means of catheter lock solutions.
Method: We reviewed the effects of single and combined anticoagulants with antibacterial catheter lock solutions or other antimicrobials for the prevention of thrombosis or infections in hemodialysis patients. Relative risks with 95% confidence intervals for trials of the same type of catheter locking solution were pooled.
Sources of information: We included original research articles in English from PubMed, EMBASE, SpringerLink, Elsevier and Ovid using the search terms 'hemodialysis,' 'central venous catheter,' 'locking solution,' 'UFH,' 'low molecular weight heparin,' 'EDTA,' 'citrate,' 'rt-PA,' 'urokinase,' 'gentamicin,' 'vancomycin', 'taurolidine,' 'sodium bicarbonate,' 'hypertonic saline' and 'ethanol' and 'catheter'.
Findings: Low-dose heparin lock solution (< 5000 U/ml) can efficiently achieve anticoagulation and will not increase the risk of bleeding. Low-concentration citrate (< 5%) combined with rt-PA can effectively prevent catheter infection and dysfunction. Catheter-related infections may be minimized by choosing the appropriate antibiotic and dose.
Limitations: There is a lack of follow-up validation data for LMWH, EDTA, taurolidine, sodium bicarbonate, ethanol, and other lock solutions.
Implications: Since catheterization is common in hemodialysis units, studies on long-term treatment and preventative strategies for catheter dysfunction and catheter-related infection are warranted.
Keywords: Hemodialysis; antibiotic lock solutions; central venous catheter; tissue plasminogen activators.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Similar articles
-
Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients.Clin J Am Soc Nephrol. 2014 Jul;9(7):1232-9. doi: 10.2215/CJN.11291113. Epub 2014 Jun 26. Clin J Am Soc Nephrol. 2014. PMID: 24970874 Free PMC article.
-
Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.Kidney Int. 2018 Mar;93(3):753-760. doi: 10.1016/j.kint.2017.06.026. Epub 2017 Sep 8. Kidney Int. 2018. PMID: 28890326 Clinical Trial.
-
Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial.Trials. 2014 Nov 19;15:449. doi: 10.1186/1745-6215-15-449. Trials. 2014. PMID: 25409678 Free PMC article. Clinical Trial.
-
Citrate versus heparin lock for prevention of hemodialysis catheter-related complications: updated systematic review and meta-analysis of randomized controlled trials.Int Urol Nephrol. 2019 Jun;51(6):1019-1033. doi: 10.1007/s11255-019-02150-0. Epub 2019 Apr 22. Int Urol Nephrol. 2019. PMID: 31012037
-
Taurolidine and Heparin as Catheter Lock Solution for Central Venous Catheters in Hemodialysis.Am J Ther. 2024 Jul-Aug 01;31(4):e398-e409. doi: 10.1097/MJT.0000000000001736. Epub 2024 May 7. Am J Ther. 2024. PMID: 38710029 Review.
Cited by
-
The current status and evolution of hemodialysis catheters.Ren Fail. 2025 Dec;47(1):2524523. doi: 10.1080/0886022X.2025.2524523. Epub 2025 Jul 3. Ren Fail. 2025. PMID: 40605543 Free PMC article. Review.
-
Evaluating tissue plasminogen activator (tPA) in dialysis catheter dysfunction: A focus on fibrin sheath and risk factors.Am Heart J Plus. 2025 Aug 18;58:100595. doi: 10.1016/j.ahjo.2025.100595. eCollection 2025 Oct. Am Heart J Plus. 2025. PMID: 40894458 Free PMC article.
-
The Tunnelled Atrial Catheter: A Promising Solution for Vascular Capital Depletion in Dialysis despite Associated Thrombi.Case Rep Nephrol. 2024 Mar 15;2024:5219914. doi: 10.1155/2024/5219914. eCollection 2024. Case Rep Nephrol. 2024. PMID: 38525052 Free PMC article.
-
A Systematic Review of the Impact of Antibiotic and Antimicrobial Catheter Locks on Catheter-Related Infections in Adult Patients Receiving Hemodialysis.Cureus. 2023 Sep 10;15(9):e45000. doi: 10.7759/cureus.45000. eCollection 2023 Sep. Cureus. 2023. PMID: 37829985 Free PMC article. Review.
-
Effect of Quorum Sensing Molecule Farnesol on Mixed Biofilms of Candida albicans and Staphylococcus aureus.Antibiotics (Basel). 2023 Feb 23;12(3):441. doi: 10.3390/antibiotics12030441. Antibiotics (Basel). 2023. PMID: 36978309 Free PMC article.
References
-
- Lok CE, Huber TS, Lee T, et al. ; National Kidney Foundation . KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1–S164. - PubMed
-
- Poinen K, Quinn RR, Clarke A, et al. . Complications from tunneled hemodialysis catheters: a canadian observational cohort study. Am J Kidney Dis. 2019;73(4):467–475. - PubMed
-
- Beathard G. Dysfunction of new catheters by old fibrin sheaths. Semin Dial. 2004;17(3):243–244. - PubMed
-
- Chu G, Fogarty GM, Avis LF, et al. . Low dose heparin lock (1000 U/mL) maintains tunnelled hemodialysis catheter patency when compared with high dose heparin (5000 U/mL): a randomised controlled trial. Hemodial Int. 2016;20(3):385–391. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials